Insider Transactions in Q2 2021 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-26.01%
|
$225,000
$30.02 P/Share
|
|
Jun 10
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+38.8%
|
$7,500
$1.11 P/Share
|
|
Jun 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-34.89%
|
$34,800
$29.85 P/Share
|
|
Jun 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
Jun 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$10,800
$27.74 P/Share
|
|
Jun 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|
|
May 10
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-27.82%
|
$195,000
$26.87 P/Share
|
|
May 10
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+38.8%
|
$7,500
$1.11 P/Share
|
|
May 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-59.85%
|
$32,400
$27.0 P/Share
|
|
May 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
May 06
2021
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,085,784
-24.08%
|
-
|
|
May 05
2021
|
Column Group L P > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,619,652
+38.64%
|
-
|
|
May 05
2021
|
Column Group L P > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
2,976,054
-83.43%
|
-
|
|
May 05
2021
|
Column Group L P > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
4,000,000
-58.92%
|
-
|
|
May 03
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
800
-5.48%
|
$27,200
$34.99 P/Share
|
|
May 03
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+5.19%
|
$5,600
$7.26 P/Share
|
|
Apr 28
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
800
-49.84%
|
$28,000
$35.25 P/Share
|
|
Apr 28
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+33.26%
|
$800
$1.86 P/Share
|
|
Apr 12
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-27.59%
|
$202,500
$27.72 P/Share
|
|
Apr 12
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+28.2%
|
$0
$0.98 P/Share
|
|
Apr 12
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-59.85%
|
$32,400
$27.2 P/Share
|
|
Apr 12
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
Apr 05
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$14,000
$35.0 P/Share
|
|
Apr 05
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|
|
Apr 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$12,400
$31.55 P/Share
|
|
Apr 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|